MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):346-347. doi: 10.15585/mmwr.mm7010e1.
Since December 2020, the Minnesota Department of Health (MDH) Public Health Laboratory has been receiving 100 specimens per week (50 from each of two clinical partners) with low cycle threshold (Ct) values for routine surveillance for SARS-CoV-2, the virus that causes COVID-19. On January 25, 2021, MDH identified the SARS-CoV-2 variant P.1 in one specimen through this surveillance system using whole genome sequencing, representing the first identified case of this variant in the United States. The P.1 variant was first identified in travelers from Brazil during routine airport screening in Tokyo, Japan, in early January 2021 (1). This variant has been associated with increased transmissibility (2), and there are concerns that mutations in the spike protein receptor-binding domain might disrupt both vaccine-induced and natural immunity (3,4). As of February 28, 2021, a total of 10 P.1 cases had been identified in the United States, including the two cases described in this report, followed by one case each in Alaska, Florida, Maryland, and Oklahoma (5).
自 2020 年 12 月以来,明尼苏达州卫生厅(MDH)公共卫生实验室每周接收 100 份标本(两个临床合作伙伴各 50 份),这些标本的低循环阈值(Ct)值用于对导致 COVID-19 的 SARS-CoV-2 病毒进行常规监测。2021 年 1 月 25 日,MDH 通过该监测系统使用全基因组测序在一份标本中发现了 SARS-CoV-2 变体 P.1,这是美国首例该变体。P.1 变体最初是在 2021 年 1 月初日本东京机场常规筛查中从来自巴西的旅行者中发现的(1)。该变体与传染性增加有关(2),人们担心刺突蛋白受体结合域的突变可能会破坏疫苗诱导和自然免疫(3,4)。截至 2021 年 2 月 28 日,美国共发现 10 例 P.1 病例,包括本报告中描述的两例病例,随后在阿拉斯加、佛罗里达、马里兰州和俄克拉荷马州各发现一例(5)。